Struwe Johan
Strama-Swedish Strategic Programme Against Antibiotic Resistance, Department of Epidemiology, Swedish Institute for Infections Disease Control, Solna, Sweden.
Wien Klin Wochenschr. 2008;120(9-10):268-79. doi: 10.1007/s00508-008-0977-6.
Sweden has been in the favorable situation of having limited antibiotic resistance and low antibiotic consumption. When pneumococci with reduced susceptibility to penicillin and methicillin-resistant Staphylococcus aureus emerged during the 1990s, professionals and relevant authorities called for extensive action plans to avoid the critical threshold levels of resistance experienced in other countries. The purpose of this paper is to examine Swedish experiences in light of new and future challenges by reviewing Swedish data on antibiotic resistance and antibiotic use, notifications, outbreak control, action plans and scientific papers. The tradition of liberal performance of clinical cultures, together with well functioning diagnostic laboratories, has formed a basis for close collaboration and development of surveillance within quality assurance programs. For more than 20 years the pharmacy monopoly in Sweden has made it possible to collect well defined data on antibiotic sales at the county level with almost 100% coverage. Multisectorial collaboration was set up in regional Strama (Swedish Strategic Programme Against Antibiotic Resistance) groups. Large diagnosis-prescribing surveys have been undertaken, and the concept of basic hygiene precautions was introduced, together with extensive programs for early case finding. However, surveillance has been hampered by inadequate IT systems and some difficulties in collecting relevant data on antibiotic sales at the national level. Also, a decentralized system with 21 counties and regions has resulted in divergence of action plans and rules. The containment of antibiotic resistance thus far may be explained by the early response in human and veterinary medicine and close multisectorial collaboration, supported by the government, before problems got out of hand. Nevertheless, rapidly growing problems with bacteria that produce extended beta-lactamases have recently emerged and antibiotic sales have started to increase again. The outcome of ongoing revision of legislation and surveillance will have great impact on the future possibilities of limiting antibiotic resistance in Sweden.
瑞典一直处于抗生素耐药性有限且抗生素消费量较低的有利形势。在20世纪90年代出现对青霉素敏感性降低的肺炎球菌和耐甲氧西林金黄色葡萄球菌时,专业人员和相关当局呼吁制定广泛的行动计划,以避免出现其他国家所经历的耐药性临界阈值水平。本文的目的是通过回顾瑞典关于抗生素耐药性和抗生素使用、通报、疫情控制、行动计划及科学论文的数据,来审视面对新的和未来挑战时瑞典的经验。临床培养自由开展的传统,加上运转良好的诊断实验室,为质量保证项目内监测的密切合作与发展奠定了基础。20多年来,瑞典的药品专卖制度使得能够在县级收集定义明确的抗生素销售数据,覆盖率几乎达到100%。在区域Strama(瑞典抗抗生素耐药性战略计划)小组中建立了多部门合作机制。开展了大规模的诊断-处方调查,引入了基本卫生预防措施的概念,以及广泛的早期病例发现项目。然而,监测工作受到信息技术系统不足以及在国家层面收集抗生素销售相关数据存在一些困难的阻碍。此外,由21个县和地区组成的分散系统导致了行动计划和规则的差异。迄今为止,抗生素耐药性得到控制可能要归功于在问题失控之前,人类和兽医学领域的早期应对以及政府支持下的密切多部门合作。尽管如此,最近出现了产超广谱β-内酰胺酶细菌的快速增长问题,抗生素销售也再次开始增加。正在进行的立法修订和监测的结果将对瑞典未来限制抗生素耐药性的可能性产生重大影响。